

Year Ended 30 June 2021 Highlights

Funds Applied

During the year ended 30 June 2021 the Board approved Public Health Entity (PHE) budget requests of \$11.55M, against which \$6.41M was spent by PHEs. This was advanced for various purposes such as:

- Equipment (research and non-research);
- Research and PHE-staff Professional Development;
- Conferences and Training;
- Other expenditure such as Volunteer support.

More details of expenditure funded can be found in pages 23-24 of the 2020-21 HSCGB Annual Report.

Highlights of Funds Applied

Set out on pages 30-31 of the HSCGB Annual Report are some of the projects and programs that have been funded in 2020-21. An example of the research being funded includes clinical testing of new T-cell therapies for adult and paediatric patients with aggressive primary brain cancer and contributions towards the Biobank which provides tumour tissue samples for medical research to improve patient outcomes. Other items funded include the a perinatal care quality improvement program and SA Paediatric chronic pain service, the PINI Program which is the Preventing Neurological Injury Initiative with preterm infants, various equipment purchases and various support to the hospital volunteer programs.

Income

Total income for 2020-21 of \$23.213M was significantly higher than the previous year. Following the significant investment market correction that occurred with the onset of Covid-19 in March 2020, there has been a substantial improvement in investment values and improved investment returns. Bequest income was higher in 2020-21 (124% higher), due to several large estates being received by the Board (further details of this income can be found in the Statement of Comprehensive Income and Notes 4 and 8 in the audited financial statements that are part of the Annual Report).

Of the \$7.255M received in Bequests and other Gifts and Donations:

- 91% was received for RAH and TQEH;
- 3% for WCH;
- 6% for SA Pathology and Hanson Centre;

The investment performance for the portfolios under management for the Board was:

Portfolio	1 yr return	3 yr pa return
HSCGB Pool	11.0%	5.5%
The Ray & Shirl Norman Cancer Research Trust	19.6%	8.3%
DE Brown Charitable Trust	10.6%	*4.1%
PF Beinke (RAH)	*9.7%	**n/a
PF Beinke (FMC)	*9.7%	**n/a
PF Beinke (RAH)	*9.7%	**n/a

* Funds SA reported earnings rate

** Trusts were established in July 2020

More details of income for the year can be found in pages 14-15 of the 2020-21 HSCGB Annual Report.

At 30 June 2021, a total of \$157.62M was held by the Board. Of this sum 84% was held on behalf of the RAH and TQEH. More details can be found at Note 10 of the financial statements as contained in the 2020-21 HSCGB Annual Report.

The activities of the Board are audited by the Auditor General. His report can be found at page 41 of the 2020-21 HSCGB Annual Report.